Mutant p53 expression is a reliable diagnostic adjunct and adverse prognosis indicator for many tumors, such as ovarian and endometrial carcinoma, uterine leiomyosarcoma, urothelial carcinoma, gastric carcinoma, and high-grade B-cell lymphoma. Here, TP53 is linked to B-cell non-Hodgkin lymphoma.